Skip to main content

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • For Subscribers
    • For Advertisers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • For Subscribers
    • For Advertisers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleCARDIOVASCULAR

Activation of Peroxisome Proliferator-Activated Receptor α by Substituted Urea-Derived Soluble Epoxide Hydrolase Inhibitors

Xiang Fang, Shanming Hu, Takaho Watanabe, Neal L. Weintraub, Gary D. Snyder, Jianrong Yao, Yi Liu, John Y.-J. Shyy, Bruce D. Hammock and Arthur A. Spector
Journal of Pharmacology and Experimental Therapeutics July 2005, 314 (1) 260-270; DOI: https://doi.org/10.1124/jpet.105.085605
Xiang Fang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shanming Hu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Takaho Watanabe
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Neal L. Weintraub
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gary D. Snyder
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jianrong Yao
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yi Liu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John Y.-J. Shyy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bruce D. Hammock
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Arthur A. Spector
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Soluble epoxide hydrolase (sEH) plays a major role in regulating vascular epoxyeicosatrienoic acid metabolism and function, and substituted urea derivatives that inhibit sEH activity reduce blood pressure in hypertensive rats. We found that substituted urea derivatives containing a dodecanoic acid group, besides effectively inhibiting sEH, increased peroxisome proliferator-activated receptor (PPAR) α activity. In PPARα transfected COS-7 cells, treatment with 10 μM N-cyclohexyl-N′-dodecanoic acid urea (CUDA) or N-adamantanyl-N′-dodecanoic acid urea (AUDA) produced 6- and 3-fold increases, respectively, in PPARα activation. Neither CUDA nor AUDA activated PPARδ or PPARγ directly, indicating selectivity for PPARα. CUDA did not alter PPARα protein expression, and it competitively inhibited the binding of Wy-14643 (pirinixic acid) to the ligand binding domain of PPARα, suggesting that it functions as a PPARα ligand. CUDA and AUDA were metabolized to chain-shortened β-oxidation products, a process that reduced their potency as sEH inhibitors and their ability to bind and activate PPARα. N,N′-Dicylclohexylurea and N-cyclohexyl-N′-dodecylurea, sEH inhibitors that do not contain a carboxylic acid group, did not activate PPARα. In HepG2 cells, CUDA increased the expression of the PPARα-responsive gene carnitine palmitoyltransferase 1A. We conclude that CUDA and AUDA, by virtue of their carboxylic acid substitution, activate PPARα in addition to potently inhibiting sEH. Further development of these compounds could lead to a class of agents with hypotensive and lipid-lowering properties that may be valuable for the prevention and treatment of cardiovascular disease.

Footnotes

  • The work at the University of Iowa was supported in part by American Heart Association Scientist Development Grant 0230096N (to X.F.), National Institutes of Health Grants HL072845 (to A.A.S.), HL070860 (to N.L.W.), and HL062984 (to N.L.W. and A.A.S.), and a Veterans Administration Merit Award (to N.L.W.). The work at the University of California (Davis) was supported by National Institutes of Health Grants HL59699 and ES02710, the Superfund Basic Research Program P42 ES04699, and National Institute of Environmental Health Sciences Centers P30 ES05707 and P01 ES11269 (to B.D.H.).

  • Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.

  • doi:10.1124/jpet.105.085605.

  • ABBREVIATIONS: EET, epoxyeicosatrienoic acid; DHET, dihydroxyeicosatrienoic acid; sEH, soluble epoxide hydrolase; DCU, N,N′-dicylclohexylurea; CDU, N-cyclohexyl-N′-dodecylurea; CUDA, N-cyclohexyl-N′-dodecanoic acid urea; AUDA, N-adamantidyl-N′-dodecanoic acid urea; PPAR, peroxisome proliferator-activated receptor; DMEM, Dulbecco's modified Eagle's medium; β-Gal, β-galactosidase; DMSO, dimethyl sulfoxide; CPT1A, carnitine palmitoyltransferase 1A; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; Wy-14643, pirinixic acid; HPLC, high-performance liquid chromatography; LC/MS-MS, liquid chromatography combined with tandem mass spectrometry; GW7647, 2-(4-(2-(1-cyclohexanebutyl-3-cyclohexylureido)ethyl)phenylthio)-2-methylpropionic acid; TLC, thin-layer chromatography.

    • Received March 2, 2005.
    • Accepted March 25, 2005.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

Log in using your username and password

Forgot your user name or password?

Pay Per Article - You may access this article (from the computer you are currently using) for 1 day for US$35.00

Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.

Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 368 (3)
Journal of Pharmacology and Experimental Therapeutics
Vol. 368, Issue 3
1 Mar 2019
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Activation of Peroxisome Proliferator-Activated Receptor α by Substituted Urea-Derived Soluble Epoxide Hydrolase Inhibitors
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
Citation Tools
Research ArticleCARDIOVASCULAR

Activation of Peroxisome Proliferator-Activated Receptor α by Substituted Urea-Derived Soluble Epoxide Hydrolase Inhibitors

Xiang Fang, Shanming Hu, Takaho Watanabe, Neal L. Weintraub, Gary D. Snyder, Jianrong Yao, Yi Liu, John Y.-J. Shyy, Bruce D. Hammock and Arthur A. Spector
Journal of Pharmacology and Experimental Therapeutics July 1, 2005, 314 (1) 260-270; DOI: https://doi.org/10.1124/jpet.105.085605

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleCARDIOVASCULAR

Activation of Peroxisome Proliferator-Activated Receptor α by Substituted Urea-Derived Soluble Epoxide Hydrolase Inhibitors

Xiang Fang, Shanming Hu, Takaho Watanabe, Neal L. Weintraub, Gary D. Snyder, Jianrong Yao, Yi Liu, John Y.-J. Shyy, Bruce D. Hammock and Arthur A. Spector
Journal of Pharmacology and Experimental Therapeutics July 1, 2005, 314 (1) 260-270; DOI: https://doi.org/10.1124/jpet.105.085605
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • SGLT2 Inhibitor and Cardioprotection
  • Pharmacology of Aprocitentan in Hypertension
  • Initial characterization of transgenic mice overexpressing human histamine H2 receptors
Show more Cardiovascular

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2019 by the American Society for Pharmacology and Experimental Therapeutics